OBI Pharma granted patent approval for its 2nd Generation Active Immunotherapy Treatment by Taiwan and Australia

Clarification on the news article by Economic Daily News E-Paper
November 4, 2016
Clarification on the news article by Economic Daily News
December 22, 2016

1.Date of occurrence of the event: 23 Nov 2016
2.Company name: OBI Pharma
3.Relationship to the Company (please enter “head office” or  “subsidiaries”): Head Office
4.Reciprocal shareholding ratios: N/A
5.Cause of occurrence: Company pipeline product OBI-833 was granted a product patent for its ” Vaccines with higher carbohydrate antigen density and novel saponin adjuvant.” Patent offices in both Taiwan and Australian issued the patent approval notices; Taiwan Patent Application No. 103100353, and Australia Patent Application No. 2014203977.
6.Countermeasures:  None
7.Any other matters that need to be specified: None